HIA
RPRX icon

Harbor Investment Advisory’s Royalty Pharma RPRX Stock Holding History

Harbor Investment Advisory’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4
Closed -$105 – 1277
2024
Q2 		$105 Buy
+4
New +$111 ﹤0.01% 1254

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbor Investment Advisory's RPRX Position: Q3 2024 in Review

Harbor Investment Advisory sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 4 shares — an estimated $105 sold.

Harbor Investment Advisory first reported a position in RPRX in Q2 2024 and held it in 1 quarter. The position peaked at $105 in Q2 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • Harbor Investment Advisory reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • Harbor Investment Advisory sold 4 Royalty Pharma shares in Q3 2024, an estimated $105.
  • Harbor Investment Advisory first reported a position in Royalty Pharma in Q2 2024 and held it in 1 quarter.
  • Harbor Investment Advisory's Royalty Pharma position peaked at $105 in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Harbor Investment Advisory's 13F filing for Q3 2024, filed 4 Oct 2024.